The path to appropriate biosimilar management by Jim Rebello May 10, 2021Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy
Trends in Oncology: A Focus on Medical Pharmacy Spend by Magellan Rx Management October 26, 2020Biosimilars, Magellan Health, Magellan RX, Magellan Rx Management, Medical Pharmacy, Medical Pharmacy Spend, Medical Pharmacy Trend Report, Oncology, Oncology Biosimilars, Oncology Spend, Pharmacy Trends, Specialty Spend
The Future is Now: The 17th Annual Specialty Summit by Magellan Rx Management September 11, 2020Biosimilars, COVID-19, Future of Genomics, Future of Specialty Pharmacy, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, Magellan Rx Management Specialty Summit, MRx Specialty Summit, Oncology Biosimilars, Precision Medicine in Oncology, specialty drugs
Traditional Drug to Biologic: A Change 10 Years in the Making by Lara Frick June 22, 2020Biologics, Biosimilars, Drug Approvals, FDA, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Traditional Drugs
Biosimilars & Their Impact on Medical Pharmacy Spend by Magellan Health Insights June 1, 2020Biosimilars, Magellan Health, Magellan RX, Magellan Rx Management, Magellan Rx Trend Report, Medical Injectable Drugs, Oncology Support, Trend Report
Top 10 Takeaways: 2019 Medical Pharmacy Trend Report by Kristen Reimers April 21, 2020Billion Dollar Drugs, Biosimilars, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, Medical Pharmacy, Medical Pharmacy Management, Medical Pharmacy Trend Report, Oncology Biosimilars, Specialty Clinical Solutions, Specialty Medications
Trend Alert: FDA Approvals – A Year in Review by Lara Frick March 22, 2019Biosimilars, FDA, FDA Approvals, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, New Drug Therapy Approvals, Novel drugs, Orphan Drugs, Rare Diseases
MRx Pipeline by Maryam Tabatabai November 30, 2018Biosimilars, Drug Pipeline, Emerging therapeutics, FDA, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, MRx Pipeline, Orphan Drugs, Specialty Medications
